Australian Nuclear Science & Technology Organisation

LuPSMA Therapy Shows Promise in Earlier Stages of Prostate Cancer

• A Peter Mac-led study reveals that Lutetium-177 PSMA-617 (LuPSMA) therapy significantly improves outcomes for patients with newly diagnosed prostate cancer when combined with standard care. • The UpFrontPSMA phase 2 trial demonstrated that adding LuPSMA to androgen deprivation therapy and chemotherapy led to undetectable PSA levels in 41% of patients, compared to 16% with standard care alone. • The trial's results, published in Lancet Oncology and presented at ESMO Congress 2024, suggest LuPSMA could be a game-changer in earlier-stage prostate cancer treatment, pending confirmation in larger phase 3 trials.